1333 related articles for article (PubMed ID: 10728742)
1. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group.
Tugwell P; Wells G; Strand V; Maetzel A; Bombardier C; Crawford B; Dorrier C; Thompson A
Arthritis Rheum; 2000 Mar; 43(3):506-14. PubMed ID: 10728742
[TBL] [Abstract][Full Text] [Related]
2. Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group.
Strand V; Tugwell P; Bombardier C; Maetzel A; Crawford B; Dorrier C; Thompson A; Wells G
Arthritis Rheum; 1999 Sep; 42(9):1870-8. PubMed ID: 10513801
[TBL] [Abstract][Full Text] [Related]
3. Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis.
Strand V; Scott DL; Emery P; Kalden JR; Smolen JS; Cannon GW; Tugwell P; Crawford B;
J Rheumatol; 2005 Apr; 32(4):590-601. PubMed ID: 15801012
[TBL] [Abstract][Full Text] [Related]
4. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
Cohen S; Cannon GW; Schiff M; Weaver A; Fox R; Olsen N; Furst D; Sharp J; Moreland L; Caldwell J; Kaine J; Strand V
Arthritis Rheum; 2001 Sep; 44(9):1984-92. PubMed ID: 11592358
[TBL] [Abstract][Full Text] [Related]
5. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial.
Pincus T; Strand V; Koch G; Amara I; Crawford B; Wolfe F; Cohen S; Felson D
Arthritis Rheum; 2003 Mar; 48(3):625-30. PubMed ID: 12632413
[TBL] [Abstract][Full Text] [Related]
6. Continuous indices of core data set measures in rheumatoid arthritis clinical trials: lower responses to placebo than seen with categorical responses with the American College of Rheumatology 20% criteria.
Pincus T; Amara I; Koch GG
Arthritis Rheum; 2005 Apr; 52(4):1031-6. PubMed ID: 15818698
[TBL] [Abstract][Full Text] [Related]
7. A cross sectional assessment of health status instruments in patients with rheumatoid arthritis participating in a clinical trial. Minocycline in Rheumatoid Arthritis Trial Group.
Tuttleman M; Pillemer SR; Tilley BC; Fowler SE; Buckley LM; Alarcón GS; Trentham DE; Neuner R; Clegg DO; Leisen JC; Heyse SP
J Rheumatol; 1997 Oct; 24(10):1910-5. PubMed ID: 9330931
[TBL] [Abstract][Full Text] [Related]
8. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis.
Kosinski M; Zhao SZ; Dedhiya S; Osterhaus JT; Ware JE
Arthritis Rheum; 2000 Jul; 43(7):1478-87. PubMed ID: 10902749
[TBL] [Abstract][Full Text] [Related]
9. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial.
Mease PJ; Revicki DA; Szechinski J; Greenwald M; Kivitz A; Barile-Fabris L; Kalsi J; Eames J; Leirisalo-Repo M
J Rheumatol; 2008 Jan; 35(1):20-30. PubMed ID: 18050385
[TBL] [Abstract][Full Text] [Related]
10. Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response.
Kosinski M; Kujawski SC; Martin R; Wanke LA; Buatti MC; Ware JE; Perfetto EM
Am J Manag Care; 2002 Mar; 8(3):231-40. PubMed ID: 11915973
[TBL] [Abstract][Full Text] [Related]
11. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
Quinn MA; Conaghan PG; O'Connor PJ; Karim Z; Greenstein A; Brown A; Brown C; Fraser A; Jarret S; Emery P
Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102
[TBL] [Abstract][Full Text] [Related]
12. Combination treatment with leflunomide and methotrexate for patients with active rheumatoid arthritis.
Lee SS; Park YW; Park JJ; Kang YM; Nam EJ; Kim SI; Lee JH; Yoo WH; Lee SI
Scand J Rheumatol; 2009; 38(1):11-4. PubMed ID: 19191187
[TBL] [Abstract][Full Text] [Related]
13. Generic quality-of-life assessment in rheumatoid arthritis.
Tugwell P; Idzerda L; Wells GA
Am J Manag Care; 2007 Dec; 13 Suppl 9():S224-36. PubMed ID: 18095786
[TBL] [Abstract][Full Text] [Related]
14. Improved functional ability in patients with rheumatoid arthritis--longterm treatment with leflunomide versus sulfasalazine. European Leflunomide Study Group.
Kalden JR; Scott DL; Smolen JS; Schattenkirchner M; Rozman B; Williams BD; Kvien TK; Jones P; Williams RB; Oed C; Rosenburg R;
J Rheumatol; 2001 Sep; 28(9):1983-91. PubMed ID: 11550964
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study.
Furst DE; Saag K; Fleischmann MR; Sherrer Y; Block JA; Schnitzer T; Rutstein J; Baldassare A; Kaine J; Calabrese L; Dietz F; Sack M; Senter RG; Wiesenhutter C; Schiff M; Stein CM; Satoi Y; Matsumoto A; Caldwell J; Harris RE; Moreland LW; Hurd E; Yocum D; Stamler DA
Arthritis Rheum; 2002 Aug; 46(8):2020-8. PubMed ID: 12209503
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study.
Kalden JR; Schattenkirchner M; Sörensen H; Emery P; Deighton C; Rozman B; Breedveld F
Arthritis Rheum; 2003 Jun; 48(6):1513-20. PubMed ID: 12794818
[TBL] [Abstract][Full Text] [Related]
17. Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate.
Rigby W; Ferraccioli G; Greenwald M; Zazueta-Montiel B; Fleischmann R; Wassenberg S; Ogale S; Armstrong G; Jahreis A; Burke L; Mela C; Chen A
Arthritis Care Res (Hoboken); 2011 May; 63(5):711-20. PubMed ID: 21557525
[TBL] [Abstract][Full Text] [Related]
18. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
[TBL] [Abstract][Full Text] [Related]
19. A comparison of valdecoxib and naproxen in the treatment of rheumatoid arthritis symptoms.
Williams GW; Kivitz AJ; Brown MT; Verburg KM
Clin Ther; 2006 Feb; 28(2):204-21. PubMed ID: 16678642
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of valdecoxib in treating the signs and symptoms of severe rheumatoid arthritis: a 12-week, multicenter, randomized, double-blind, placebo-controlled study.
Gibofsky A; Rodrigues J; Fiechtner J; Berger M; Pan S
Clin Ther; 2007 Jun; 29(6):1071-85. PubMed ID: 17692722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
